Seminars in Oncology
Volume 34, Issue 4 , Pages 311-320 , August 2007

Guidelines for the Surgical Management of Pancreatic Adenocarcinoma

  • Michael B. Ujiki
    • ,
  • Mark S. Talamonti

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark S. Talamonti, MD, Division of Surgical Oncology, 675 N St Clair, Galter 10-105, Chicago, IL 60611.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Brunschwig A. A one-stage pancreaticoduodenectomy. Surg Gynecol Obstet. 1937;65:681–684
  3. Halsted W. Contributions to the surgery of the bile passages, especially the common bile duct. Boston Med Surg J. 1899;141:645–654
  4. Whipple A, Parson W, Mullins C. Treatment of carcinoma of the ampulla of Vater. Ann Surg. 1935;102:763–779
  5. Crile G. The advantages of bypass operations over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet. 1970;130:1049–1053
  6. Shapiro TM. Adenocarcinoma of the pancreas: A statistical analysis of biliary bypass vs. Whipple resection in good risk patients. Ann Surg. 1975;182:715–721
  7. Crist D, Sitzman J, Cameron J. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987;206:358–365
  8. Trede M, Schwall G, Saeger H. Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447–458
  9. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database. J Am Coll Surg. 1999;189:1–7
  10. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410–1427
  11. McCarthy MJ, Evans J, Sagar G, et al. Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg. 1998;85:320–325
  12. Chong M, Freeny PC, Schmiedl UP. Pancreatic arterial anatomy: Depiction with dual-phase helical CT. Radiology. 1998;208:537–542
  13. Vedantham S, Lu DS, Reber HA, Kadell B. Small peripancreatic veins: Improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. Am J Roentgenol. 1998;170:377–383
  14. Roche CJ, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. Am J Roentgenol. 2003;180:475–480
  15. Gulliver D, Baker M, Cheng C. Malignant biliary obstruction: efficacy of thin-sction dynamic CT in determining resectability. Am J Roentgenol. 1992;159:503–507
  16. Freeny P, Traverso L, Ryan J. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg. 1993;165:600–606
  17. Fuhrman G, Charnsangavej C, Abbruzzese J. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg. 1994;167:104–113
  18. Wayne JD, Abdalla EK, Wolff RA, et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist. 2002;7:34–45
  19. Ichikawa T, Haradome H, Hachiya J, et al. Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging. Radiology. 1997;202:655–662
  20. Megibow AJ, Zhou XH, Rotterdam H, et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability-report of the Radiology Diagnostic Oncology Group. Radiology. 1995;195:327–332
  21. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–1046
  22. Sendler A, Avril N, Helmberger H, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg. 2000;24:1121–1129
  23. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259–264
  24. Diederichs CG, Staib L, Glatting G. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030–1033
  25. Rosch T, Lightdale C, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721–1726
  26. Rosch T, Dittler HJ, Strobel K, et al. Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: A blind reevaluation of the videotapes. Gastrointest Endosc. 2000;52:469–474
  27. Rosch T. Staging of pancreatic cancer: Analysis of literature results. Gastrointest Endosc Clin N Am. 1995;5:735–739
  28. Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg. 2003;7:118–126
  29. Stewart CJ, Mills PR, Carter R, et al. Brush cytology in the assessment of pancreatico-biliary strictures: A review of 406 cases. J Clin Pathol. 2001;54:449–455
  30. Tanaka M. Intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2004;28:282–288
  31. Povoski SP, Karpeh MS, Conlon KC, et al. Association of preoperative biliary drainage with postoperative outcome following pancreatoduodenectomy. Ann Surg. 1999;230:131–142
  32. Pisters PW, Hudec WA, Hess KR, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001;234:47–55
  33. Sewnath M, Birjmohun R, Rauws E, et al. The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J Am Coll Surg. 2001;192:726–734
  34. Sohn TA, Yeo CJ, Cameron JL, et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications?. J Gastrointest Surg. 2000;4:258–268
  35. Ritts RE, Pitt HA. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am. 1998;7:93–101
  36. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas. 1994;9:731–734
  37. Ritts RE, Nagorney DM, Jacobsen DJ. Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas. 1994;9:707–716
  38. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951–956
  39. Katz A, Hanlon A, Lanciano R. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393–396
  40. Warshaw AL, Gu ZY, Wittenberg J. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg. 1990;125:230–233
  41. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy in pancreatic cancer. Am J Surg. 1986;151:76–80
  42. Conlon KC, Dougherty E, Klimstra DS. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223:134–140
  43. Friess H, Kleff J, Silva JC. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg. 1998;186:675–682
  44. Barreiro CJ, Lillemoe KD, Konairis LG. Diagnostic laparoscopy for periampullary and pancreatic cancer: What is the true benefit?. J Gastrointest Surg. 2002;6:75–81
  45. Pisters PW, Lee JE, Vauthey JN. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88:325–337
  46. Jimenez RE, Warshaw AL, Rattner DW. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135:409–415
  47. Nieveen Van Dijkum EJ, Romijn MG, Terwee CB. Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann Surg. 2003;237:66–73
  48. Montgomery RC, Hoffman JP, Riley LB. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4:551–556
  49. John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and periampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg. 1995;221:156–164
  50. Evans DB, Pisters PWT, Lee JE. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In:  Baker RJ,  Fischer JE editor. Mastery of Surgery. New York, NY: Lippincott Williams & Wilkins; 2001;p. 1299–1318
  51. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized control trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355–368
  52. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—Part 3: Update on 5-year survival. J Gastrointest Surg. 2005;9:1191–1206
  53. Pedrazzoli P, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Ann Surg. 1998;228:508–517
  54. Bold RJ, Charnsangavej C, Cleary KR. Major vascular resection as part of pancreaticoduodenectomy for cancer: Radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg. 1999;3:233–243
  55. Bachellier P, Nakano H, Oussoultzoglou PD, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?. Am J Surg. 2001;182:120–129
  56. Sasson AR, Hoffman JP, Ross EA, et al. En bloc resection for locally advanced cancer of the pancreas: Is it worthwhile?. J Gastrointest Surg. 2002;6:147–158
  57. Nakagohri T, Kinoshita T, Konishi M, et al. Survival benefits of portal vein resection for pancreatic cancer. Am J Surg. 2003;186:149–153
  58. van Genen RC, ten Kate FJ, de Wit LT, et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery. 2001;129:158–163
  59. Harrison LE, Brennan MF. Portal vein resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am. 1998;7:165–181
  60. Talamonti MS, Small W, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:1–9
  61. Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreatoduodenectomy. Br J Surg. 1999;86:603–607
  62. Tran K, Smeenk H, van Eijck C, Kazmeir J. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: A randomized, multicenter stuffy of 170 patients with pancreatic or periampullary tumors. Ann Surg. 2004;240:738–745
  63. Lerut JP, Gianello PR, Otte JB, Kestens PJ. Pancreaticoduodenal resection: Surgical experience and evaluation of risk factors in 103 patients. Ann Surg. 1984;199:432–437
  64. Hertner FP, Cooperman AM, Ahlborn TN, et al. Surgical experience with pancreatic and periampullary cancer. Ann Surg. 1982;195:274–281
  65. Aston SJ, Longmire WP. Pancreaticoduodenal resection: twenty years experience. Arch Surg. 1973;106:813–817
  66. Schlitt HJ, Schmidt U, Simunec D, et al. Morbidity and mortality associated with pancreatogastrostomy and pancreatojejunostomy following partial pancreatoduodenectomy. Br J Surg. 2002;89:1245–1251
  67. Yeo CJ, Cameron JL, Maher MM, et al. A prospective trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 1995;222:580–588
  68. Sikora S, Posner M. Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg. 1995;82:1590–1597
  69. Bassi C, Falconi M, Molinari E, et al. Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: Results of a prospective randomized trial. Surgery. 2003;134:766–771
  70. Balcom JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg. 2001;136:391–398
  71. Bassi C, Falconi M, Salvia R, et al. Role of octreotide in the treatment of external pancreatic pure fistulas: A single-institution prospective experience. Arch Surg. 2000;385:10–13
  72. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg. 2000;232:419–429
  73. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226:632–641
  74. Ohtsuka T, Yamaguchi K, Chijiiwa K, et al. Postoperative pancreatic exocrine function influences body weight maintenance after pylorus-preserving pancreatoduodenectomy. Am J Surg. 2001;182:524–529
  75. Lillemoe KD, Cameron JL, Hardcare JM, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer?. A prospective randomized trial. 1999;230:322–330
  76. Birkmeyer JD, Warshaw AL, Finlayson SR, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery. 1999;126:178–183
  77. Delcore R, Rodriguez FJ, Forster J, et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 1996;172:463–468
  78. Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–329
  79. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg. 1997;226:248–260
  80. Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume: Toward the end of completion pancreatectomy. Ann Surg. 2000;232:786–795
  81. Buchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection. Arch Surg. 2003;138:1310–1314
  82. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: Critical analysis of 221 resections. World J Surg. 1999;23:164–172
  83. Cunningham JD, Weyant MT, Levitt M, et al. Complications requiring reoperations following pancreatectomy. Int J Pancreatol. 1998;24:23–29
  84. Farley DR, Schwall G, Trede M. Completion pancreatectomy for surgical complications after pancreatoduodenectomy. Br J Surg. 1996;83:176–179
  85. Halloran CM, Ghaneh P, Bosonnet L, et al. Complications of pancreatic cancer resection. Dig Surg. 2002;19:138–146
  86. Rosemurgy AS, Bloomston M, Serfini FM. Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg. 2001;5:21–26
  87. Zervos EE, Rosemurgy AS, Al-Saif O, et al. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004;11:23–31
  88. Yeo CJ, Barry MK, Sauter PK, et al. Erythromycin accelerates gastric emptying after pancreatoduodenectomy (A prospective, randomized, placebo-controlled trial). Ann Surg. 1993;218:229–238
  89. Bakkevold KE, Kmbstad B. Morbidity and mortality after radical and palliative pancreatic cancer surgery: Risk factors influencing the short-term results. Ann Surg. 1993;217:356–368
  90. Buchler MW, Friess H, Wagner M, et al. Pancreatic fistula after pancreatic head resection. Br J Surg. 2000;87:883–889
  91. Conlon KC, Labow D, Leung D, et al. Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg. 2001;234:487–493
  92. Cullen JJ, Sarr MG, Ilstrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: Incidence, significance, and management. Am J Surg. 1994;168:295–298
  93. van Berge Henegouwen MI, de Witt LT, van Gulik TM, et al. Incidence, risk factors, and treatment of pancreatic leakage after pancreatoduodenectomy: Drainage versus resection of pancreatic remnant. J Am Coll Surg. 1997;185:18–25
  94. Sohn TA, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications. J Gastrointest Surg. 2003;7:209–219
  95. Rumstadt B, Schwab M, Korth P, et al. Hemorrhage after pancreatoduodenectomy. Ann Surg. 1998;227:236–241
  96. Allma JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069–2076
  97. Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998;227:821–831
  98. Luttges J, Vogel I, Menke M, et al. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch. 1998;433:237–242
  99. Karpoff HM, Klimstra DS, Brennan MF, et al. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg. 2001;136:44–47
  100. Ihse I, Anderson H, Andren-Sandberg A. Total pancreatectomy for cancer of the pancreas: Is it appropriate?. World J Surg. 1996;20:288–294

PII: S0093-7754(07)00099-1

doi: 10.1053/j.seminoncol.2007.05.004

Seminars in Oncology
Volume 34, Issue 4 , Pages 311-320 , August 2007

Article Tools

* Image Usage & Resolution